Zurcher Kantonalbank Zurich Cantonalbank Purchases 4,088 Shares of Catalent, Inc. (NYSE:CTLT)

Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Catalent, Inc. (NYSE:CTLT) by 12.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 37,982 shares of the company’s stock after acquiring an additional 4,088 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Catalent were worth $2,301,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Nisa Investment Advisors LLC raised its stake in Catalent by 1.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after purchasing an additional 185 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Catalent by 1.1% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock valued at $1,179,000 after buying an additional 220 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of Catalent by 2.6% in the third quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock valued at $553,000 after buying an additional 229 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its position in Catalent by 3.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock worth $432,000 after buying an additional 278 shares in the last quarter.

Catalent Trading Up 0.5 %

Shares of CTLT stock opened at $61.72 on Wednesday. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $62.08. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The stock has a market cap of $11.20 billion, a price-to-earnings ratio of -27.31, a PEG ratio of 2.44 and a beta of 1.15. The stock has a 50-day moving average of $59.96 and a 200-day moving average of $58.60.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.10) EPS. On average, equities research analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on CTLT shares. William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com upgraded Catalent from a “sell” rating to a “hold” rating in a report on Monday. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Catalent currently has a consensus rating of “Hold” and a consensus target price of $63.40.

Insider Buying and Selling

In related news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock valued at $305,931 over the last quarter. Insiders own 0.31% of the company’s stock.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.